腎臓がん治療薬の市場規模、シェア、成長分析：がんの種類別、治療法別、薬剤クラス別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

腎臓がん治療薬市場規模は2023年に61億米ドルとなり、予測期間（2025～2032年）のCAGRは6.4%で、2024年の64億9,000万米ドルから2032年には106億6,000万米ドルに成長する見通しです。

世界の腎臓がん治療薬市場は、医学研究の進歩と効果的な治療への注目の高まりにより、大きな変貌を遂げつつあります。標的療法や免疫療法の革新は、患者により効率的で侵襲の少ない選択肢を提供し、意識の高まりや早期発見への取り組みと一致しています。製薬会社とヘルスケア機関の戦略的提携は、新薬の開発を促進しています。在宅医療やオンライン薬局の分野での成長は注目に値しますが、伝統的な病院やオフラインの薬局が支配的であることに変わりありません。北米が市場をリードしていますが、APAC地域が急速に勢いを増しています。患者中心の治療へのシフトは腎臓がん患者のQOL向上に重点を置いており、市場関係者は研究開発への投資を促されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩
• 貿易分析

腎臓がん治療薬市場規模：がんの種類別

• 市場概要
• 腎細胞がん（RCC）
• 移行上皮がん
• ウィルムス腫瘍
• 腎肉腫

腎臓がん治療薬市場規模：治療法別

• 市場概要
• 標的療法
• 免疫療法
• 化学療法
• その他の治療法

腎臓がん治療薬市場規模：薬剤クラス別

• 市場概要
• 血管新生阻害剤
• モノクローナル抗体
• mTOR阻害剤
• サイトカイン免疫療法（IL-2）
• その他の薬物クラス

腎臓がん治療薬市場規模：投与経路別

• 市場概要
• オーラル
• 静脈内
• 皮下

腎臓がん治療薬市場規模：流通チャネル別

• 市場概要
• 病院薬局
• レンガとモルタル
• eコマース

腎臓がん治療薬市場規模：最終用途別

• 市場概要
• 病院薬局
• 小売薬局
• その他

腎臓がん治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Astellas Pharma Inc.（Japan）
• AstraZeneca PLC（United Kingdom）
• Bayer AG（Germany）
• Bristol-Myers Squibb Company（United States）
• Eisai Co., Ltd.（Japan）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GSK plc（United Kingdom）
• Helsinn Healthcare SA（Switzerland）
• Johnson & Johnson Services, Inc.（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Seattle Genetics（United States）
• Abbott Laboratories（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim（Germany）
• CSL Vifor（Switzerland）
• Chugai Pharmaceutical Co., Ltd.（Japan）

結論と提言

Kidney Cancer Drugs Market size was valued at USD 6.1 billion in 2023 and is poised to grow from USD 6.49 billion in 2024 to USD 10.66 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The global kidney cancer drugs market is experiencing significant transformations, driven by advancements in medical research and an increasing focus on effective treatments. Innovations in targeted therapies and immunotherapies are providing patients with more efficient, less invasive options, coinciding with growing awareness and early detection initiatives. Strategic collaborations between pharmaceutical companies and healthcare institutions are fostering the development of novel drugs. While growth is notable in the homecare and online pharmacy segments, traditional hospitals and offline pharmacies continue to dominate. North America leads the market, but the APAC region is rapidly gaining momentum. A shift towards patient-centric care emphasizes improving quality of life for kidney cancer patients, prompting market players to invest in R&D, ultimately enhancing patient outcomes and shaping the future of treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Kidney Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Kidney Cancer Drugs Market Segments Analysis

Global Kidney Cancer Drugs Market is segmented by Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use and region. Based on Cancer Type, the market is segmented into Renal cell carcinoma (RCC), Transitional cell cancer, Wilms tumor and Renal sarcoma. Based on Therapy, the market is segmented into Targeted therapy, Immunotherapy, Chemotherapy and Other therapies. Based on Drug Class, the market is segmented into Angiogenesis inhibitors, Monoclonal antibodies, mTOR inhibitors, Cytokine immunotherapy (IL-2) and Other drug classes. Based on Route of Administration, the market is segmented into Oral, Intravenous and Subcutaneous. Based on Distribution Channel, the market is segmented into Hospital pharmacy, Brick and mortar and E-commerce. Based on End Use, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Kidney Cancer Drugs Market

Immunotherapy serves as a significant catalyst for the expansion of the kidney cancer drugs market. By harnessing the body's immune system to specifically target and destroy cancer cells, this innovative treatment has demonstrated promising efficacy in managing kidney cancer, offering hope in scenarios where conventional treatments may fall short. Ongoing research aimed at discovering new combination therapies and immunotherapeutic agents is facilitating the development of less invasive and more effective treatment options. As a result, patients are now presented with improved opportunities for positive outcomes in their fight against kidney cancer, marking a transformative shift in the landscape of cancer treatment.

Restraints in the Kidney Cancer Drugs Market

A significant challenge facing the kidney cancer drugs market is the ongoing regulatory obstacles. While these stringent regulatory frameworks are essential for ensuring patient safety and the effectiveness of new drugs, they often result in extended approval timelines. This lengthy process, which includes comprehensive clinical trials and intricate documentation, can considerably delay the availability of innovative therapies. Moreover, the complexities of obtaining global approvals are exacerbated by differing regulatory requirements across regions. These combined issues ultimately restrict the timely launch of potentially life-saving treatments for kidney cancer, thereby reducing the range of options available to patients battling this illness.

Market Trends of the Kidney Cancer Drugs Market

The kidney cancer drugs market is witnessing a significant trend towards personalized treatment paradigms, driven by advancements in molecular diagnostics and genetic profiling. These innovations enable the identification of specific biomarkers that inform the development of tailored therapies, addressing the unique characteristics of each patient. This personalized approach not only enhances treatment efficacy but also minimizes adverse side effects, significantly improving patient outcomes. As healthcare providers increasingly adopt these customized strategies, the market is expected to evolve, focusing on innovative drug formulations and precision medicine, ultimately transforming the landscape of kidney cancer care and driving growth in the pharmaceutical sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global Kidney Cancer Drugs Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Renal cell carcinoma (RCC)
• Transitional cell cancer
• Wilms tumor
• Renal sarcoma

Global Kidney Cancer Drugs Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Targeted therapy
• Immunotherapy
• Chemotherapy
• Other therapies

Global Kidney Cancer Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Angiogenesis inhibitors
• Monoclonal antibodies
• mTOR inhibitors
• Cytokine immunotherapy (IL-2)
• Other drug classes

Global Kidney Cancer Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous

Global Kidney Cancer Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital pharmacy
• Brick and mortar
• E-commerce

Global Kidney Cancer Drugs Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Kidney Cancer Drugs Market Size & CAGR (2025-2032)

• North America (Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use)
  • US
  • Canada
• Europe (Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Healthcare SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Vifor (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations